


WHAT ARE THE MODULEN® IBD STRENGTHS?

Nestlé know-how enables to preserve **health-promoting bioactives** delivering sustained benefits over time.




Milk naturally contains bioactives that are beneficial for health. Among them is **TGF-β**, an immunoregulatory molecule involved in modulation of inflammation pathways & tissue repairs mechanisms.^{1,2}



Manufacturing process in Nestlé factory preserves sustained **TGF-β** and other beneficial bioactives.



Preserved **TGF-β** in **Modulen® IBD** formulation is shown to contribute to reduce inflammation and support mucosal barrier recovery.³



Cost-effectiveness analysis shows that over the course of one year, **Modulen® IBD** proves to be cost-effective compared to standard ONS, by being less costly (-10%) and more effective and leading to a higher number of remissions.¹⁸



50+ studies

Modulen® IBD has been shown to efficiently support management of Crohn's Disease in pediatric and adult patients with a positive impact on growth and nutrition status.¹⁴⁻¹⁷



Response rate > **80%**

Achievement of mucosal healing in **89%**

Modulen® IBD can be used as Exclusive Enteral Nutrition, Partial Enteral Nutrition (PEN) or as part of the Crohn's Disease Exclusion Diet+PEN in the **ModuLife™** program for induction and maintenance of remission in Crohn's Disease patients.⁴⁻¹³



The anti-inflammatory property of **Modulen® IBD** was recently reported in other inflammatory condition such as acute gastrointestinal Graft Versus Host Disease.¹⁹



Reference: 1. Donnet-Hughes *et al.* Immunology and Cell Biology. 2000;78:74-79. 2. Feagins L. Inflammatory Bowel Diseases. 2010;16(11):1963-68. 3. Boumessed *et al.* DDW 2023 (Mo 1702). 4. Fell *et al.* Aliment Pharmacol Ther. 2000 Mar;14(3):281-9. 5. Berni Canani *et al.* Dig Liver Dis. 2006 Jun;38(6):381-7. 6. Triantafyllidis *et al.* Annals of Gastroenterology. 2006;19(1):66-71. 7. Borrelli *et al.* Clin Gastroenterol Hepatol. 2006 Jun;4(6):744-53. 8. Duncan *et al.* BMC Gastroenterol. 2014 Mar 20;14:50. 9. Navas-Lopez *et al.* An Pediatr (Barc). 2015 Jul;83(1):47-54. 10. Pigneur *et al.* J Crohns Colitis. 2019 Jul 25;13(7):846-55. 11. Logan *et al.* Aliment Pharmacol Ther. 2019;50:664-674. 12. Levine *et al.* Gastroenterology. 2019;157:440-450. 13. Bischoff *et al.* Clin. Nutr. 41 2023;352-379. 14. Gavin *et al.* J Hum Nutr Diet. 2005 Oct;18(5):337-42. 15. Gerasimidis *et al.* Inflamm Bowel Dis. 2012 Sep;18(9):1672-81. 16. Werkstetter *et al.* Ann Nutr Metab. 2013;63(1-2):10-6. 17. Boumessed *et al.* Int J Mol Sci. 2021;22(8):4025. 18. Wooller *et al.* ISPOR Europe 2023 (EE586). 19. Morello *et al.* Nutrients 2022, 14, 3589.